Changes in gene activity in the DNA of multiple myeloma cells can lead to the progression of the disease by shutting down the expression of…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Janssen Biotech and Bristol-Myers Squibb will collaborate in a clinical trial program to evaluate the combination of Darzalex (daratumumab) and Opdivo (nivolumab) in multiple myeloma…
Adding the proteasome inhibitor Velcade (bortezomib) to the standard therapy of Revlimid (lenalidomide) and dexamethasone — a triple combo therapy — significantly extends progression-free survival and…
Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism also was linked to a…
Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
